REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.

David M WeinreichSumathi SivapalasingamThomas NortonShazia AliHaitao GaoRafia BhoreJing XiaoAndrea T HooperJennifer D HamiltonBret J MusserDiana RofailMohamed HusseinJoseph ImDominique Y AtmodjoChristina PerryCynthia PanAdnan MahmoodRomana HosainJohn D DavisKenneth C TurnerAlina BaumChristos A KyratsousYunji KimAmanda CookWendy KampmanLilia Roque-GuerreroGerard AcloqueHessam AazamiKevin CannonJ Abraham Simón-CamposJoseph A BocchiniBari KowalA Thomas DiCioccioYuhwen SooGregory P GebaNeil StahlLeah LipsichNed BraunsteinGary HermanGeorge D Yancopoulosnull null

Published in: The New England journal of medicine (2021)

REGEN-COV reduced the risk of Covid-19-related hospitalization or death from any cause, and it resolved symptoms and reduced the SARS-CoV-2 viral load more rapidly than placebo. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT04425629.).

Keyphrases

sars cov
respiratory syndrome coronavirus
coronavirus disease
randomized controlled trial
metabolic syndrome
double blind
sleep quality
phase iii
skeletal muscle